EBERECHI ANI: Open Payments
NPI 1801332051 · FONTANA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,800 in 206 payments from 13 companies in 2025. Trend: 2023 $2,278 · 2024 $2,146 · 2025 $3,800
Food & beverage: $3,800
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 41 | $701 |
| Alkermes, Inc. | 35 | $636 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 30 | $629 |
| Teva Pharmaceuticals USA, Inc. | 20 | $363 |
| Janssen Pharmaceuticals, Inc | 14 | $347 |
| Vanda Pharmaceuticals Inc. | 16 | $326 |
| ABBVIE INC. | 16 | $195 |
| Lundbeck LLC | 9 | $183 |
| Axsome Therapeutics, Inc. | 13 | $149 |
| Neurocrine BioSciences, Inc. | 4 | $110 |
Products named: REXULTI, CAPLYTA, ARISTADA, AUSTEDO XR, INVEGA SUSTENNA, FANAPT, ABILIFY ASIMTUFII, VRAYLAR.
Industry payments across CA — which companies pay providers there.
